Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis.
Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis.
复制标题
H5N1 流感疫苗在老年人中的免疫原性：系统评价和荟萃分析
DOI：
10.1080/21645515.2020.1777822
复制
发表时间：
2021-02-01
影响因子：
4.8
通讯作者：
Huang J
中科院分区：
文献类型：
--
作者：
Zhang K;Wu X;Shi Y;Gou X;Huang J
已经生产了几种不同的疫苗供人类使用，以预防高致病性H5 N1流感。一些研究报告说，流感疫苗在老年人中的临床有效性可能低于年轻人。本研究对老年人接种H5 N1流感疫苗的免疫原性进行了荟萃分析。检索EMBASE、PubMed、科克伦图书馆、中国维普、万方、CBM等数据库。荟萃分析共纳入10篇文章中的3951名老年人。与单剂相比，两剂H5 N1疫苗导致更高的血清转化和血清保护。对于用佐剂疫苗处理的所有组，在两次免疫后血清转化率（SCR）和血清保护率（SPR）显著增加（1.55- 2.16倍）。水包油乳剂（OE）佐剂7.5 μg疫苗引起的抗体应答高于3.75 μ g疫苗（SCR：风险比（RR）= 1.26（1.19，1.33）; SPR：RR = 1.25（1.14，1.36））。仅当给予7.5 μg OE佐剂疫苗时，老年人的抗体应答略低于年轻人（SCR：RR = 1.06（1.01，1.11））。7.5 μg OE佐剂疫苗接种后，最常见的不良反应为注射部位疼痛、肿胀和红斑，发生率分别为32%、3%和2%，未发现严重不良反应，表明两剂7.5 μg OE佐剂H5 N1疫苗在老年人中耐受性良好，并诱导了稳健的抗体应答。
Several different vaccines have been produced for human use to prevent the highly pathogenic H5N1 influenza. Some studies reported that the clinical effectiveness of influenza vaccines in older adults may be lower than in younger adults. In this study, a meta-analysis of the immunogenicity of H5N1 influenza vaccines in elderly adults was performed. Database search was conducted in EMBASE, PubMed, the Cochrane Library, Chinese VIP, Wanfang and CBM. A total of 3951 elderly adults from 10 articles were included in the meta-analysis. Compared to a single dose, two doses of H5N1 vaccines resulted in the higher seroconversion and seroprotection. For all groups treated with adjuvanted vaccines, there were significant increases (1.55- to 2.16-fold) in the seroconversion rates (SCRs) and seroprotection rates (SPRs) after two immunizations. Oil-in-water emulsion (OE)-adjuvanted 7.5 μg vaccine caused higher antibody responses than 3.75 μg of vaccine (SCR: risk ratio (RR) = 1.26 (1.19, 1.33); SPR: RR = 1.25 (1.14, 1.36)). Elderly adults exhibited slightly lower antibody responses only when given 7.5 μg of OE-adjuvanted vaccine (SCR: RR = 1.06 (1.01, 1.11)) than younger adults. After treatment with the 7.5 μg of OE-adjuvanted vaccines, the most commonly reported adverse events were injection site pain, swelling and erythema, with the incidence of 32%, 3% and 2%, respectively, and no serious adverse events were found. These data demonstrate that two doses of 7.5 µg of OE-adjuvanted H5N1 vaccine are well tolerated and induce a robust antibody response in elderly adults.
登录
查看更多内容
DOI：
10.1093/infdis/jiq174
发表时间：
2011-04-15
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Heijmans S;De Meulemeester M;Reynders P;Giet D;Demanet E;Devresse PY;Icardi G;Dramé M;Roman F;Gillard P
通讯作者：
Gillard P
影响因子：
5.5
作者：
Diallo A;Victor JC;Feser J;Ortiz JR;Kanesa-Thasan N;Ndiaye M;Diarra B;Cheikh S;Diene D;Ndiaye T;Ndiaye A;Lafond KE;Widdowson MA;Neuzil KM
通讯作者：
Neuzil KM
影响因子：
11.8
作者：
Chan, PKS
通讯作者：
Chan, PKS
影响因子：
11.8
作者：
Cordero, Elisa;Roca-Oporto, Cristina;Perez-Romero, Pilar
通讯作者：
Perez-Romero, Pilar
影响因子：
5.5
作者：
Basavaraj, V. H.;Sampath, G.;Ella, Krishna M.
通讯作者：
Ella, Krishna M.